Agents used to treat trichomonas infections.
A genus of parasitic flagellate EUKARYOTES distinguished by the presence of four anterior flagella, an undulating membrane, and a trailing flagellum.
The mulberry plant family of the order Urticales, subclass Hamamelidae, class Magnoliopsida. They have milky latex and small, petalless male or female flowers.
A species of TRICHOMONAS that produces a refractory vaginal discharge in females, as well as bladder and urethral infections in males.

Activity of disulfiram (bis(diethylthiocarbamoyl)disulphide) and ditiocarb (diethyldithiocarbamate) against metronidazole-sensitive and -resistant Trichomonas vaginalis and Tritrichomonas foetus. (1/95)

Clinical resistance of Trichomonas vaginalis to metronidazole is best correlated with MIC values measured under aerobic conditions. Under these conditions both disulfiram (bis(diethylthiocarbamoyl)disulphide), and its first mammalian metabolite, ditiocarb (diethyldithiocarbamate), showed high levels of activity against metronidazole-sensitive (disulfiram MIC, 0.1-0.7 microM; ditiocarb MIC, 0.3-9 microM) and -resistant (MICs 0.2-1.3 microM and 1.2-9 microM respectively) isolates. Tritrichomonas foetus was also sensitive-the MICs for seven metronidazole-sensitive isolates were 0.1-1.0 microM for disulfiram and 1.0-6.9 microM for ditiocarb; those for two highly metronidazole-resistant strains were 0.3-1.3 microM and 0.6-6 microM respectively. Under anerobic conditions most strains became highly resistant to both compounds. Surprisingly, disulfiram was consistently more active than ditiocarb.  (+info)

Intestinal blockage by carcinoma and Blastocystis hominis infection. (2/95)

We detected heavy infections of Blastocystis hominis in four individuals with intestinal obstruction due to cancerous growths. After surgery, the infections spontaneously resolved, without specific chemotherapy. It appears that the B. hominis infection was coincidental and not related to the neoplastic growth. We suggest that intestinal obstruction and concomitant stool retention, plus hemorrhage from cancerous lesions, may have permitted the more abundant growth of B. hominis. This is the first report of a possible relationship between intestinal obstruction and a concomitant B. hominis infection.  (+info)

A new method for assessing metronidazole susceptibility of Giardia lamblia trophozoites. (3/95)

A quantitative, simple, and rapid assay has been developed to assess Giardia lamblia trophozoite sensitivity to metronidazole [1-(2-hydroxyetyl)-2-methyl-5-nitroimidazole] (MTZ). This new assay utilizes the ability of live (surviving) trophozoites to take up oxygen after have been exposed to MTZ. The effect of MTZ on oxygen uptake was compared with its effect on viability as evaluated by a culture method and morphological assays. Oxygen uptake rates decreased in trophozoites treated with MTZ, and this effect was drug concentration dependent: O(2) uptake rates went from 3.04 microM O(2) min(-1) per 10(6) cells to 0.72 microM O(2) min(-1) per 10(6) cells with increasing drug concentration (0.15 to 0.6 mM) in the preincubation. Concentrations of the drug which inhibited oxygen uptake by 28 to 76% in trophozoites killed from 39 to 82% of trophozoites, as evaluated by the culture method, and altered the morphology of 21 to 86% of the trophozoites. Thus, the trophozoites killed by MTZ are nonmotile cells and do not take up oxygen. A good correlation was found between the inhibitory effects of MTZ, as evaluated by oxygen uptake, and cellular viability. Similar 50% inhibitory concentrations were obtained: 0.33 mM by oxygen uptake, 0. 26 mM by the culture method, and 0.35 mM by morphological criteria. Oxygen uptake appears to be a good indicator of parasite viability. Therefore, this new method can provide a convenient means to assess MTZ susceptibility in G. lamblia and can be applied for screening potential antigiardial agents.  (+info)

Resistance of Trichomonas vaginalis to metronidazole: report of the first three cases from Finland and optimization of in vitro susceptibility testing under various oxygen concentrations. (4/95)

Trichomonas vaginalis is a globally common sexually transmitted human parasite. Many strains of T. vaginalis from around the world have been described to be resistant to the current drug of choice, metronidazole. However, only a few cases of metronidazole resistance have been reported from Europe. The resistant strains cause prolonged infections which are difficult to treat. T. vaginalis infection also increases the risk for human immunodeficiency virus transmission. We present a practical method for determining the resistance of T. vaginalis to 5-nitroimidazoles. The suggested method was developed by determining the MICs and minimal lethal concentrations (MLCs) of metronidazole and ornidazole for T. vaginalis under various aerobic and anaerobic conditions. Using this assay we have found the first three metronidazole-resistant strains from Finland, although the origin of at least one of the strains seems to be Russia. Analysis of the patient-derived and previously characterized isolates showed that metronidazole-resistant strains were also resistant to ornidazole, and MLCs for all strains tested correlated well with the MICs. The suggested MICs of metronidazole for differentiation of sensitive and resistant isolates are >75 microg/ml in an aerobic 24-h assay and >15 microg/ml in an anaerobic 48-h assay.  (+info)

A new highly effective short-term therapy schedule for Helicobacter pylori eradication. (5/95)

BACKGROUND: Although triple therapy regimens suggested in the Current European guidelines give fairly good results, several studies have reported an unsatisfactory Helicobacter pylori eradication rate (< 80%). AIM: To evaluate the efficacy of a new short-term treatment sequence on H. pylori eradication. METHODS: A total of 52 patients with H. pylori infection and either non-ulcer dyspepsia (34 patients) or peptic ulcer (18 patients) were enrolled to receive a 10-day therapy: omeprazole 20 mg b.d. plus amoxycillin 1 g b.d. for the first 5 days, followed by omeprazole 20 mg b.d., clarithromycin 500 mg b.d. and tinidazole 500 mg b.d. for the remaining 5 days. H. pylori infection at entry was assessed by rapid urease test and histology on biopsies from the antrum and the corpus. Bacterial eradication was assessed by endoscopy (peptic ulcer patients) or 13C urea breath test (non-ulcer dyspepsia patients) 4-6 weeks after therapy had ended. RESULTS: All patients completed the study. H. pylori eradication was achieved in all but one patient, with an eradication rate of 98% (95% CI: 94.3-100) with intention-to-treat analysis. Patient compliance was good (consumption of prescribed drugs > 95%) for all but one patient, who took the triple therapy regimen for 4 days instead of 5 days. No major side-effects were reported but three (6%) patients complained of mild side-effects. CONCLUSIONS: The use of this 'five plus five' therapy schedule as an initial treatment for H. pylori deserves further investigation.  (+info)

The effectiveness of omeprazole, clarithromycin and tinidazole in eradicating Helicobacter pylori in a community screen and treat programme. Leeds Help Study Group. (6/95)

INTRODUCTION: Helicobacter pylori screening and treatment has been proposed as a cost-effective method of preventing gastric cancer. AIM: To assess, in a randomized controlled trial, the efficacy of therapy in eradicating H. pylori as part of a screening programme, and to report the adverse events associated with this strategy. METHODS: Subjects between the ages of 40-49 years were randomly selected from the lists of 36 primary care centres. Participants attended their local practice and H. pylori status was determined by 13C-urea breath test. Infected subjects were randomized to receive omeprazole 20 mg b.d., clarithromycin 250 mg b.d. and tinidazole 500 mg b.d. for 7 days (OCT) or identical placebos. Eradication was determined by a 13C-urea breath test 6 months and 2 years after the first visit. Successful eradication was defined as two negative 13C-urea breath tests or one negative and one missing test. Adverse events and compliance were assessed at the 6-month visit. RESULTS: A total of 32 929 subjects were invited to attend, 8407 were evaluable, and 2329 (28%) of these were H. pylori-positive. A total of 1161 subjects were randomized to OCT and 1163 to placebo; over 80% returned for a repeat 13C-urea breath test on at least one occasion. The eradication rates in those allocated to OCT were as follows: intention-to-treat, 710 out of 1161 (61%; 95% confidence interval: 58-64%); evaluable 710 out of 967 (73%; 95% CI: 71-76%); took all medication 645 out of 769 (84%; 95% CI: 81-87%). Adverse events occurred in 45% of the treatment group and in 18% of the placebo group (relative risk 2.5; 95% CI: 2.1-2.9). Compliance, male gender, no antibiotic prescription in the subsequent 2 years and experiencing a bitter taste with the medication were independently associated with treatment success. CONCLUSIONS: The OCT regimen has an eradication rate of 61% in intention-to-treat analysis and is therefore less successful in treating H. pylori as part of a screening programme compared with hospital studies in dyspeptic patients.  (+info)

Cytopathogenic effect of Trichomonas vaginalis on human vaginal epithelial cells cultured in vitro. (7/95)

In this study we established human vaginal epithelial cells (hVECs) in culture and evaluated their interaction with Trichomonas vaginalis parasites to complement previous studies using other cell types. Primary cultures of hVECs were established. Contaminating fibroblasts were separated from epithelial cells by differential trypsinization. Specific antibody staining revealed that over 92% of cells in hVEC monolayers were epithelial cells. T. vaginalis adhered to hVECs and produced severe cytotoxic effects resulting in obliteration of the monolayer within 24 h. Adherence and cytotoxicity were not observed when T. vaginalis was exposed to human vaginal fibroblasts or bovine vaginal epithelial cells. Likewise, the bovine parasite Tritrichomonas foetus had no cytotoxic effects on hVECs. We concluded that the interaction between T. vaginalis and hVECs is both cell specific (limited to epithelial cells and not vaginal fibroblasts) and species specific (limited to human vaginal cells and not bovine cells). Pretreatment of T. vaginalis with metronidazole or periodate abolished the adhesion of parasites to cell monolayers and the cytotoxic effect, suggesting involvement of carbohydrate-containing molecules in these processes. Different clinical isolates of T. vaginalis caused damage to cultured cells at different rates. Parasites separated from the vaginal cell monolayer by a permeable membrane did not produce a cytopathic effect, suggesting contact-dependent cytotoxicity.  (+info)

Molecular epidemiology of metronidazole resistance in a population of Trichomonas vaginalis clinical isolates. (8/95)

Trichomonas vaginalis, the causative agent for human trichomoniasis, is a problematic sexually transmitted disease mainly in women, where it may be asymptomatic or cause severe vaginitis and cervicitis. Despite its high prevalence, the genetic variability and drug resistance characteristics of this organism are poorly understood. To address these issues, genetic analyses were performed on 109 clinical isolates using three approaches. First, two internal transcribed spacer (ITS) regions flanking the 5.8S subunit of the ribosomal DNA gene were sequenced. The only variation was a point mutation at nucleotide position 66 of the ITS1 region found in 16 isolates (14.7%). Second, the presence of a 5.5-kb double-stranded RNA T. vaginalis virus (TVV) was assessed. TVV was detected in 55 isolates (50%). Finally, a phylogenetic analysis was performed based on random amplified polymorphic DNA data. The resulting phylogeny indicated at least two distinct lineages that correlate with the presence of TVV. A band-sharing index indicating relatedness was created for different groups of isolates. It demonstrated that isolates harboring the virus are significantly more closely related to each other than to the rest of the population, and it indicated a high level of relatedness among isolates with in vitro metronidazole resistance. This finding is consistent with the hypothesis that drug resistance to T. vaginalis resulted from a single or very few mutational events. Permutation tests and nonparametric analyses showed associations between metronidazole resistance and phylogeny, the ITS mutation, and TVV presence. These results suggest the existence of genetic markers with clinical implications for T. vaginalis infections.  (+info)

Antitrichomonatal agents are a group of medications specifically used to treat infections caused by the protozoan parasite, Trichomonas vaginalis. The most common antitrichomonal agent is metronidazole, which works by disrupting the parasite's ability to reproduce and survive within the human body. Other antitrichomonal agents include tinidazole and secnidazole, which also belong to the nitroimidazole class of antibiotics. These medications are available in various forms, such as tablets, capsules, or topical creams, and are typically prescribed by healthcare professionals for the treatment of trichomoniasis, a common sexually transmitted infection (STI) that can affect both men and women. It is important to note that these medications should only be used under the guidance of a healthcare provider, as they may have potential side effects and drug interactions.

Trichomonas is a genus of protozoan parasites that are commonly found in the human body, particularly in the urogenital tract. The most well-known species is Trichomonas vaginalis, which is responsible for the sexually transmitted infection known as trichomoniasis. This infection can cause various symptoms in both men and women, including vaginitis, urethritis, and pelvic inflammatory disease.

T. vaginalis is a pear-shaped flagellate protozoan that measures around 10 to 20 micrometers in length. It has four flagella at the anterior end and an undulating membrane along one side of its body, which helps it move through its environment. The parasite can attach itself to host cells using a specialized structure called an adhesion zone.

Trichomonas species are typically transmitted through sexual contact, although they can also be spread through the sharing of contaminated towels or clothing. Infection with T. vaginalis can increase the risk of acquiring other sexually transmitted infections, such as HIV and human papillomavirus (HPV).

Diagnosis of trichomoniasis typically involves the detection of T. vaginalis in a sample of vaginal or urethral discharge. Treatment usually involves the administration of antibiotics, such as metronidazole or tinidazole, which are effective at killing the parasite and curing the infection.

Moraceae is not a medical term but a botanical term that refers to a family of flowering plants, also known as the mulberry family. This family includes various trees and shrubs that are widely distributed in tropical and subtropical regions around the world. Some members of this family have economic importance, such as Mulberries (Morus spp.), Figs (Ficus carica), and Breadfruit (Artocarpus altilis).

However, in a medical context, some plants from the Moraceae family may have medicinal uses. For example:
1. Ficus carica (Fig) - The latex of the fig tree has been used traditionally for treating warts and skin diseases.
2. Morus alba (White Mulberry) - Its bark is used in traditional Chinese medicine to treat diabetes, high blood pressure, and high cholesterol.
3. Artocarpus heterophyllus (Jackfruit) - Its seeds are used in traditional Ayurvedic medicine for treating diarrhea and asthma.

It's important to note that the use of these plants as medicines should be done under the guidance of a healthcare professional, as they can interact with other medications and have potential side effects.

Trichomonas vaginalis is a species of protozoan parasite that causes the sexually transmitted infection known as trichomoniasis. It primarily infects the urogenital tract, with women being more frequently affected than men. The parasite exists as a motile, pear-shaped trophozoite, measuring about 10-20 micrometers in size.

T. vaginalis infection can lead to various symptoms, including vaginal discharge with an unpleasant odor, itching, and irritation in women, while men may experience urethral discharge or discomfort during urination. However, up to 50% of infected individuals might not develop any noticeable symptoms, making the infection challenging to recognize and treat without medical testing.

Diagnosis typically involves microscopic examination of vaginal secretions or urine samples, although nucleic acid amplification tests (NAATs) are becoming more common due to their higher sensitivity and specificity. Treatment usually consists of oral metronidazole or tinidazole, which are antibiotics that target the parasite's ability to reproduce. It is essential to treat both partners simultaneously to prevent reinfection and ensure successful eradication of the parasite.

An antitrichomonal agent is an antiprotozoal agent that acts on trichomonas parasites. Examples include: furazolidone nifuratel ... MeSH list of agents 82000994 v t e (Antiprotozoal agents, All stub articles, Antiinfective agent stubs). ... nimorazole ornidazole tinidazole usnic acid Antitrichomonal+Agents at the U.S. National Library of Medicine Medical Subject ...
Ibikunle GF, Adebajo AC, Famuyiwa FG, Aladesanmi AJ, Adewunmi CO (2011). "In-vitro evaluation of anti-trichomonal activities of ... Essential Oil as a Potential Anti-Leishmania Agent: Effects on Leishmania amazonensis and Possible Mechanisms of Action". ...
... antitrichomonal agents MeSH D27.505.954.122.250.100.170 - coccidiostats MeSH D27.505.954.122.250.100.875 - trypanocidal agents ... tocolytic agents MeSH D27.505.954.016 - anti-allergic agents MeSH D27.505.954.122 - anti-infective agents MeSH D27.505.954.122. ... tranquilizing agents MeSH D27.505.696.277.950.015 - anti-anxiety agents MeSH D27.505.696.277.950.025 - antimanic agents MeSH ... fertility agents MeSH D27.505.696.875.552.344 - fertility agents, female MeSH D27.505.696.875.552.510 - fertility agents, male ...
The anti-trichomonal effect of SolcoTrichovac has led multiple researchers to investigate the possibility of shared surface ... Another study by Boos and Rüttgers investigated the therapeutic effect of SolcoTrichovac when used as a sole therapeutic agent ... Reid G (February 2001). "Probiotic agents to protect the urogenital tract against infection". The American Journal of Clinical ... Alderete, Gombošová and others however described contrary findings, and attributed any anti-trichomonal activity of ...
An antitrichomonal agent is an antiprotozoal agent that acts on trichomonas parasites. Examples include: furazolidone nifuratel ... MeSH list of agents 82000994 v t e (Antiprotozoal agents, All stub articles, Antiinfective agent stubs). ... nimorazole ornidazole tinidazole usnic acid Antitrichomonal+Agents at the U.S. National Library of Medicine Medical Subject ...
... antineovascularisation agents, enzyme/protease inhibitors, and antirheumatic agents are promising drugs targeting distinct ... Metronidazole (MTZ) is the mainstay of anti-trichomonal chemotherapy; however, drug resistance has become an increasingly ... Trichomonas vaginalis is the causative agent of trichomoniasis, the most prevalent non-viral sexually transmitted infection ... Trichomonas vaginalis is the causative agent of trichomoniasis, the most prevalent non-viral sexually transmitted infection ...
Categories: Antitrichomonal Agents Image Types: Photo, Illustrations, Video, Color, Black&White, PublicDomain, ...
8:32 Anti-trichomonal agents No observations Suriname. NGK-C-011 6.08 Anti-Protozoa: Anti-Amoeba and Anti-Giardia No ... 8:32 Anti-trichomonal agents No observations Barbados. Barbados National Drug Formulary (BNDF) 08.30 Antiprotozoals No ... 8:32 Anti-trichomonal agents No observations Bahamas. Drug Formulary 09. OBSTETRIC AND GYNAECOLOGICAL MEDICATIONS No ... 8:32 Anti-trichomonal agents No observations Haiti. National List of Essential Medicines 06.05.01 Antiamoebics and ...
毛滴蟲病(英語:Antitrichomonal agent). *硝基咪唑 (卡硝唑(英語:Carnidazole), 甲硝唑#, 替硝唑(英語:
Antitrichomonal Agents Antitrust Laws Antitubercular Agents Antitussive Agents Antivenins Antiviral Agents Antlers Antley- ... ... agent alkylating agents alkylating agent therapies alkylating-agent therapies alkylating agent therapy alkylating-agent therapy ... Anti-HIV Agents Anti-Infective Agents Anti-Infective Agents, Local Anti-Infective Agents, Urinary Anti-Inflammatory Agents Anti ... Anti-Allergic Agents Anti-Anxiety Agents Anti-Arrhythmia Agents Anti-Asthmatic Agents Anti-Bacterial Agents Anti-Dyskinesia ...
Furazolidone suspension is an anti-trichomonal drug, an anti-infective, and antibacterial agent and an inhibitor of monoamine ...
"Antitrichomonal Agents","data":{"category":"Medicine","linkRef":"Antitrichomonal Agents"}},{"value":"Antituberculotics and ... ":"Agents Which Reduce Motility","data":{"category":"Medicine","linkRef":"Agents Which Reduce Motility"}},{"value":"Agents for ... ":"Agents Used in the Treatment of Poisonings","data":{"category":"Medicine","linkRef":"Agents Used in the Treatment of ... ":"Agents for Control of Status Epilepticus"}},{"value":"Agents for Essential Tremor, Chorea and Related Disorders","data":{" ...
"Antitrichomonal Agents","data":{"category":"Medicine","linkRef":"Antitrichomonal Agents"}},{"value":"Antituberculotics and ... ":"Agents Which Reduce Motility","data":{"category":"Medicine","linkRef":"Agents Which Reduce Motility"}},{"value":"Agents for ... ":"Agents Used in the Treatment of Poisonings","data":{"category":"Medicine","linkRef":"Agents Used in the Treatment of ... ":"Agents for Control of Status Epilepticus"}},{"value":"Agents for Essential Tremor, Chorea and Related Disorders","data":{" ...
Antitrichomonal activity of metronidazole-loaded lactoferrin nanoparticles in pigeon trichomoniasis PARASITOLOGY RESEARCH 120 ( ... Development and characterization of monoterpene loaded microemulsions as novel scolicidal agents JOURNAL OF BIOMEDICAL ... Antitrichomonal activity of nanoemulsion of carvacrol on Trichomonas galline: formulation development and in vitro ... IN VITRO EVALUATION OF ANTI-TRICHOMONAL POTENTIAL OF PSIDIUM GUAJAVA LEAF ESSENTIAL OIL AND ITS MAIN COMPONENTS AGAINST ...
flowers as hematopoietic agent in an animal model. GASTROPROTECTIVE. -Protective Effect of a Polyherbal Traditional Formula ... ANTI-TRICHOMONAL. -Antibacterial and anti-Trichomonas Vaginalis effects of Rosa Damascena mill petal oil (a persian medicine ... An in vitro evaluation of various Rosa damascena flower extracts as a natural antisolar agent.. WOUND HEALING. -Combined ... Promising effects of Rosa damascena petal extracts as antioxidant and antibacterial agents. -[A new isoflavone derivative from ...
It was used as incense in religious rituals, as an embalming agent, and as a cure for many diseases including. what is now ... author treated fifty other cases with standard antitrichomonal. suppositories. The teatree oil was applied diluted by means of ...
Oral and ischial same have relieved demonstrated to ensure the V-gel brain agent and pruritis pounds in senseless fluid. In ... In these studies, Lithium was linolenic to restoril and solemn to symmetrical anti-trichomonal drugs. ... Accutane is in the enlightening buy tizanidine online classes: compulsive antineoplastics, belligerant uncategorized agents. ...
Nigerian medicinal plants have been traditionally used as anti-schistosomal agents or molluscicides, of which Tetrapleura ... in-depth characterization of purine and pyrimidine transporters provides a critical foundation for the development of new anti-trichomonal ... justifying the exploration of nucleoside analogues as therapeutic agents. Previous reports identified nucleosides with potent ...
These results suggest that mutant 471 might be a more promising anti-cancer agent than wild-type TNF. ... Kitasatospora setae NBRC 14216(T) (=KM-6054(T)) is known to produce setamycin (bafilomycin B1) possessing antitrichomonal ...
MeSH Terms: Antitrichomonal Agents/therapeutic use*; Female; Humans; Hysterectomy*; Surgical Wound Infection/prevention & ...
Antitrichomonal Agents / pharmacology* Actions. * Search in PubMed * Search in MeSH * Add to Search ... Narcisi EM, Secor WE. Narcisi EM, et al. Antimicrob Agents Chemother. 1996 May;40(5):1121-5. doi: 10.1128/AAC.40.5.1121. ... Crowell AL, Sanders-Lewis KA, Secor WE. Crowell AL, et al. Antimicrob Agents Chemother. 2003 Apr;47(4):1407-9. doi: 10.1128/AAC ... 1407-1409.2003. Antimicrob Agents Chemother. 2003. PMID: 12654679 Free PMC article. ...
Antitrichomonal Agents / adverse effects* Actions. * Search in PubMed * Search in MeSH * Add to Search ... Watson JA, Strub-Wourgraft N, Tarral A, Ribeiro I, Tarning J, White NJ. Watson JA, et al. Antimicrob Agents Chemother. 2019 Mar ... Print 2019 Apr. Antimicrob Agents Chemother. 2019. PMID: 30670439 Free PMC article. ...
Antitrichomonal Agents / metabolism Actions. * Search in PubMed * Search in MeSH * Add to Search ...
In this regard, other active agents reported in the literature are nifuratel, which is used as an antitrichomonal and ... Aminoglycosides such as neomycin are the most common allergenic antibacterial agents reported,[5] and three of our patients ... The cumulative use of quaternary ammonium antiseptic agents such as benzalkonium chloride[9] and methylbenzethonium chloride[14 ... a preservative agent in a corticosteroid cream (once); and (4) paraben mix (once), which, along with other preservatives such ...
Antitrichomonal agent Current Synonym true false 3671144018 Substance with antitrichomonal mechanism of action Current Synonym ... Substance with antitrichomonal mechanism of action (substance) {373261002 , SNOMED-CT } Parent/Child (Relationship Type) ... Substance with antitrichomonal mechanism of action (substance). Code System Preferred Concept Name. Substance with ...
Agents used to treat trichomonas infections.. Terms. Antitrichomonal Agents Preferred Term Term UI T003060. Date01/01/1999. ... Anti-Infective Agents [D27.505.954.122] * Antiparasitic Agents [D27.505.954.122.250] * Antiprotozoal Agents [D27.505.954.122. ... Agents used to treat trichomonas infections.. Entry Term(s). Antitrichomonal Drugs Antitrichomonals Trichomonicides Registry ... Antitrichomonal Agents Preferred Concept UI. M0001514. Registry Number. 0. Scope Note. ...
Agents used to treat trichomonas infections.. Terms. Antitrichomonal Agents Preferred Term Term UI T003060. Date01/01/1999. ... Anti-Infective Agents [D27.505.954.122] * Antiparasitic Agents [D27.505.954.122.250] * Antiprotozoal Agents [D27.505.954.122. ... Agents used to treat trichomonas infections.. Entry Term(s). Antitrichomonal Drugs Antitrichomonals Trichomonicides Registry ... Antitrichomonal Agents Preferred Concept UI. M0001514. Registry Number. 0. Scope Note. ...
protozoan infect; /drug ther: consider also ANTITRICHOMONAL AGENTS. Allowable Qualifiers:. BL blood. CF cerebrospinal fluid. CI ...
Tinidazole is an antiprotozoal, antibacterial agent. The nitro- group of tinidazole is reduced by cell extracts of Trichomonas. ... tinidazole was superior to placebo and comparable to other anti-trichomonal drugs. The single oral 2 g tinidazole dose was also ... Carcinogenicity has been seen in mice and rats treated chronically with metronidazole, another nitroimidazole agent ( 13.1). ... Carcinogenicity has been seen in mice and rats treated chronically with metronidazole, another nitroimidazole agent [see ...
8:32 Anti-trichomonal agents No observations Suriname. NGK-C-011 6.08 Anti-Protozoa: Anti-Amoeba and Anti-Giardia No ... 8:32 Anti-trichomonal agents No observations Barbados. Barbados National Drug Formulary (BNDF) 08.30 Antiprotozoals No ... 8:32 Anti-trichomonal agents No observations Bahamas. Drug Formulary 09. OBSTETRIC AND GYNAECOLOGICAL MEDICATIONS No ... 8:32 Anti-trichomonal agents No observations Haiti. National List of Essential Medicines 06.05.01 Antiamoebics and ...
... antitrichomonal agent, E0402608,Cerumenex,preparation for earwax removal, E0402608,Cerumenex,triethanolamine polypeptide, ... in vitro diagnostic agents, E0735602,Cobas,in vitro diagnostic agents, E0735602,cobas,in vitro diagnostic agents, E0735602, ... nootropic agents, cognitive enhancement agents, and agents for the treatment of histamine-related conditions, neurodegenerative ... agents for manufacture of soluble tablets, E0726841,solutab,agents for manufacture of soluble tablets, E0726902,Slow-K,slow- ...
Trichomonicides See Antitrichomonal Agents Trichophytia Profunda Barbae See Tinea Capitis Trichophytia Profunda Capitis See ...
8:32 Anti-trichomonal agents No observations Suriname. NGK-C-011 6.08 Anti-Protozoa: Anti-Amoeba and Anti-Giardia No ... 8:32 Anti-trichomonal agents No observations Barbados. Barbados National Drug Formulary (BNDF) 08.30 Antiprotozoals No ... 8:32 Anti-trichomonal agents No observations Bahamas. Drug Formulary 09. OBSTETRIC AND GYNAECOLOGICAL MEDICATIONS No ... 8:32 Anti-trichomonal agents No observations Haiti. National List of Essential Medicines 06.05.01 Antiamoebics and ...
BACKGROUND: Iron plays essential roles in the pathogenesis and proliferation of Trichomonas vaginalis, the causative agent of ... Metronidazole (MTZ) is the mainstay of anti-trichomonal chemotherapy; however, drug resistance has become an increasingly ... Trichomonas vaginalis is the causative agent of trichomoniasis, the most prevalent non-viral sexually transmitted infection ...
A nitroimidazole antitrichomonal agent effective against Trichomonas vaginalis, Entamoeba histolytica, and Giardia lamblia ... Anti-Ulcer Agents. Various agents with different action mechanisms used to treat or ameliorate PEPTIC ULCER or irritation of ... Anti-Inflammatory Agents, Non-Steroidal. Anti-inflammatory agents that are non-steroidal in nature. In addition to anti- ... Several of the compounds in this class are ANTI-ULCER AGENTS that act by inhibiting the POTASSIUM HYDROGEN ATPASE found in the ...
"Antitrichomonal Agents","data":{"category":"Medicine","linkRef":"Antitrichomonal Agents"}},{"value":"Antituberculotics and ... ":"Agents Which Reduce Motility","data":{"category":"Medicine","linkRef":"Agents Which Reduce Motility"}},{"value":"Agents for ... ":"Agents Used in the Treatment of Poisonings","data":{"category":"Medicine","linkRef":"Agents Used in the Treatment of ... ":"Agents for Control of Status Epilepticus"}},{"value":"Agents for Essential Tremor, Chorea and Related Disorders","data":{" ...
"Antitrichomonal Agents","data":{"category":"Medicine","linkRef":"Antitrichomonal Agents"}},{"value":"Antituberculotics and ... ":"Agents Which Reduce Motility","data":{"category":"Medicine","linkRef":"Agents Which Reduce Motility"}},{"value":"Agents for ... ":"Agents Used in the Treatment of Poisonings","data":{"category":"Medicine","linkRef":"Agents Used in the Treatment of ... ":"Agents for Control of Status Epilepticus"}},{"value":"Agents for Essential Tremor, Chorea and Related Disorders","data":{" ...
57706 Nitric oxide synthase inhibitor 118762 Non-steroidal antiinflammatory agent 113354 Nootropic 119931 Nucleotide metabolism ... 74248 Antispirochetal 105438 Antitoxic 111742 Antitrichomonal 106559 Antitrypanosomal 68966 Antitussive 61262 Antitussive, ... 16738 Acetylcholine neuromuscular blocking agent 78391 Acetylcholine nicotinic agonist 57340 Acetylcholine nicotinic antagonist ...
... anti-foaming agent,noun,E0438501,foaming agent,noun,E0583387,no anti-,anti-foam,adj,E0222816,foam,verb,E0028347,no anti-,anti- ... antitrichomonal,noun,E0009766,trichomonal,adj,E0062086,no anti,antitropic,adj,E0009767,tropic,noun,E0062323,no anti,antitrust, ... antifoaming agent,noun,E0438501,foaming agent,noun,E0583387,no anti,antifoam,adj,E0222816,foam,verb,E0028347,no anti,antifoam, ...
... anti-foaming agent,noun,E0438501,foaming agent,noun,E0583387,no anti-,anti-foam,adj,E0222816,foam,verb,E0028347,no anti-,anti- ... antitrichomonal,noun,E0009766,trichomonal,adj,E0062086,no anti,antitropic,adj,E0009767,tropic,noun,E0062323,no anti,antitrust, ... antifoaming agent,noun,E0438501,foaming agent,noun,E0583387,no anti,antifoam,adj,E0222816,foam,verb,E0028347,no anti,antifoam, ...
  • An antitrichomonal agent is an antiprotozoal agent that acts on trichomonas parasites. (wikipedia.org)
  • Agents used to treat trichomonas infections. (nih.gov)
  • In this regard, other active agents reported in the literature are nifuratel, which is used as an antitrichomonal and antimycotic agent and as an antiseptic in antihemorrhoidal ointments and suppositories, and usnic acid. (medscape.com)
  • Carcinogenicity has been seen in mice and rats treated chronically with metronidazole, another nitroimidazole agent ( 13.1 ). (nih.gov)
  • Various agents with different action mechanisms used to treat or ameliorate PEPTIC ULCER or irritation of the gastrointestinal tract. (lookformedical.com)
  • Aminoglycosides such as neomycin are the most common allergenic antibacterial agents reported, [ 5 ] and three of our patients reacted to it. (medscape.com)
  • [ 5 ] The rather high sensitization rate of the preservative agents methylchloroisothiazolinone and mixed methyldibromoglutaronitrile and 2-phenoxyethanol (Euxyl K400, Schülke & Mayr GmbH, Norderstedt, Germany) has been attributed to their widespread use in cosmetic and toiletry items, including moistened toilet paper, to which one of our patients reacted because of sensitization to both the methylchloroisothiazolinone and bromonitropropanediol (a formaldehyde releaser) in it. (medscape.com)